Cargando…

Telomere length predicts for outcome to FCR chemotherapy in CLL

We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR) and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we used a high-throughput version of the assay (HT-STELA) to establish whether telomere length could pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norris, Kevin, Hillmen, Peter, Rawstron, Andrew, Hills, Robert, Baird, Duncan M., Fegan, Christopher D., Pepper, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756045/ https://www.ncbi.nlm.nih.gov/pubmed/30700843 http://dx.doi.org/10.1038/s41375-019-0389-9

Ejemplares similares

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

Telomere fusions associate with coding sequence and copy number alterations in CLL
por: Escudero, Laura, et al.
Publicado: (2019)

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial
por: Strefford, JC, et al.
Publicado: (2015)

Telomere Length Dynamics and the Evolution of Cancer Genome Architecture
por: Cleal, Kez, et al.
Publicado: (2018)

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
por: Howard, Dena R., et al.
Publicado: (2016)

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
por: Nichols, Eva-Maria, et al.
Publicado: (2015)

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses
por: Rawstron, Andrew C., et al.
Publicado: (2022)

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
por: Davids, Matthew S., et al.
Publicado: (2020)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

Measuring telomere length and telomere dynamics in evolutionary biology and ecology
por: Nussey, Daniel H, et al.
Publicado: (2014)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

Unidimensional scales for fears of cancer recurrence and their psychometric properties: the FCR4 and FCR7
por: Humphris, G. M., et al.
Publicado: (2018)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

Human FcR Polymorphism and Disease
por: Li, Xinrui, et al.
Publicado: (2014)

Experiences in the design and implementation of phase II trials in CLL
por: Cohen, Dena R, et al.
Publicado: (2011)

A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial
por: Toogeh, Gholamreza, et al.
Publicado: (2018)

Blood Cell Telomere Length Is a Dynamic Feature
por: Svenson, Ulrika, et al.
Publicado: (2011)

Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis
por: Garcia-Martin, I., et al.
Publicado: (2017)

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
por: Linley, Adam J., et al.
Publicado: (2021)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017)

Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients
por: Simpson, K., et al.
Publicado: (2015)

Newborn telomere length predicts later life telomere length: Tracking telomere length from birth to child- and adulthood
por: Martens, Dries S., et al.
Publicado: (2021)

PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation
por: Ngo, Greg, et al.
Publicado: (2018)

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
por: Collett, Laura, et al.
Publicado: (2017)

T cell memory revisited using single telomere length analysis
por: Roger, Laureline, et al.
Publicado: (2023)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

Interpretation of normal anatomic structures on chest radiography: Comparison of Fuji Computed Radiography (FCR) 5501D with FCR 5000 and screen‐film system
por: Nakashima, Kazuaki, et al.
Publicado: (2003)

Feed Conversion Ratio (FCR) and Performance Group Estimation Based on Predicted Feed Intake for the Optimisation of Beef Production
por: Davison, Chris, et al.
Publicado: (2023)

Reproducibility of telomere length assessment: an international collaborative study
por: Martin-Ruiz, Carmen M, et al.
Publicado: (2015)

Reproducibility of Telomere Length Assessment - An International Collaborative Study
por: Martin-Ruiz, Carmen M., et al.
Publicado: (2015)

Blocking of FcR Suppresses the Intestinal Invasion of Scrapie Agents
por: Uraki, Ryuta, et al.
Publicado: (2011)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Telomeres and Telomere Length: A General Overview
por: Srinivas, Nalini, et al.
Publicado: (2020)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Telomere Length Regulation
por: Lansdorp, Peter
Publicado: (2022)

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition
por: Pepper, C, et al.
Publicado: (2015)

Structural and functional analysis of the human POT1-TPP1 telomeric complex
por: Rice, Cory, et al.
Publicado: (2017)

Telomere length as a predictive biomarker in osteoporosis (Review)
por: Kakridonis, Fotios, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3tn7lhdg2kh0otfana2crjpni